Hui Cai
Corporate Officer/Principal chez WUXI APPTEC CO., LTD.
Profil
Hui Cai is currently the VP-Corporate Alliances & Communications at WuXi AppTec Co., Ltd.
Prior to this, Dr. Cai held the position of Vice President-Corporate Development at HUYA Bioscience International LLC and President at Inflexion BioPartners, Inc. Dr. Cai's education includes a doctorate from The Scripps Research Institute, undergraduate and graduate degrees from Peking University, and an MBA from the University of California San Diego.
Postes actifs de Hui Cai
| Sociétés | Poste | Début |
|---|---|---|
| WUXI APPTEC CO., LTD. | Corporate Officer/Principal | - |
Anciens postes connus de Hui Cai
| Sociétés | Poste | Fin |
|---|---|---|
| Inflexion BioPartners, Inc. | President | - |
HUYA Bioscience International LLC
 HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
Formation de Hui Cai
| The Scripps Research Institute | Doctorate Degree |
| Peking University | Graduate Degree |
| University of California San Diego | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| WUXI APPTEC CO., LTD. | Health Technology |
| Entreprise privées | 2 |
|---|---|
HUYA Bioscience International LLC
HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Health Technology |
| Inflexion BioPartners, Inc. |
